Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23229636 | 0.76 | HPGD (0.40) | HPGDALDH1A1L3MBTL1 | |
| SCHEMBL25137362 | 0.71 | RAB9A (0.36) | TDP1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL11609722 | 0.67 | KMT2A (0.43) | RAB9AKMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL20214069 | 0.67 | RAB9A (0.33) | RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18570151 | 0.65 | KDM4E (0.32) | TDP1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL2454582 | 0.65 | — | — | |
| SCHEMBL1492015 | 0.64 | HPGD (0.46) | TDP1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL25137331 | 0.63 | RECQL (0.35) | RAB9AKMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL4774709 | 0.63 | ALDH1A1 (0.33) | RAB9AKMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL270481 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206903-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-02-19 | — | — | US | disclosed |
| US-20160030390-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Ed ucation on behalf of the University of Nevada Ren (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2014144606-A2 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20060189639-A1 | Antagonists of the mGlu receptor and uses thereof | ABBOTT LABORATORIES | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206903-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | TDP1 554/4885RAB9A 1131/4885KMT2A 3360/4885 |
| US-20060189639-A1 | Antagonists of the mGlu receptor and uses thereof | GRM3, GRM4, GRIA4 | TDP1 1981/4885RAB9A 2965/4885KMT2A 1923/4885 |
| US-20160030390-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | TDP1 554/4885RAB9A 1131/4885KMT2A 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.